CD274 and neoplasm: Another FDA-approved example for treatment in recurrent or metastatic HNSCC is the immune checkpoint inhibitor Pembrolizumab, which binds to tumor cells expressing high levels of PD-L1 and achieved a response rate of ~20% in clinical trials; however, it led to hyperprogressive tumor disease in some patients [21,22].